Back

Elevated suicidal thoughts and behaviors among adults reporting symptoms of Cannabinoid Hyperemesis Syndrome: Results from a national survey of US adults

Hicks, B. M. M.; Price, A.; Goldman, P.; Ilgen, M. A.

2026-02-28 gastroenterology
10.64898/2026.02.26.26347185 medRxiv
Show abstract

ObjectiveAs cannabis use has increased in the United States, so has cannabinoid hyperemesis syndrome (CHS), a disorder characterized by severe nausea, vomiting, and abdominal pain among heavy cannabis users. We previously showed that CHS symptoms are associated with several behavioral and psychological characteristics linked to psychosocial impairment. We examined links between CHS symptoms and suicidal thoughts, behaviors, and proximal suicide risk factors. MethodsWe used data from the National Firearms, Alcohol, Cannabis, and Suicide survey, a nationally representative survey of 7,034 US adults. Items assessed symptoms of CHS and suicidal thoughts and behaviors. Comparisons focused on: those with daily cannabis use and CHS symptoms (n = 191), those with daily cannabis use without CHS symptoms (n = 882), those with past year cannabis use but not daily use (n = 1288), and those without past year cannabis use (n = 4673). ResultsThose with CHS symptoms reported the highest prevalence of suicidal thoughts and behaviors with most lifetime rates being significantly higher than those with daily cannabis use without CHS symptoms. Those with CHS symptoms also reported higher mean-levels of thoughts and feelings associated with suicide (i.e., perceived burdensomeness, thwarted belongingness, defeat, entrapment) than all the other groups. ConclusionsThose with CHS symptoms reported especially high rates of suicidal thoughts, behaviors, and attempts even when compared to others with daily cannabis use. People with CHS symptoms appear to be at high risk of suicide, possibly related to distress from their gastrointestinal symptoms and psychiatric, substance use, and medical comorbidities.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
American Journal of Preventive Medicine
11 papers in training set
Top 0.1%
14.4%
2
PLOS ONE
4510 papers in training set
Top 20%
9.2%
3
PLOS Medicine
98 papers in training set
Top 0.5%
6.4%
4
Translational Psychiatry
219 papers in training set
Top 1%
4.3%
5
Scientific Reports
3102 papers in training set
Top 31%
4.0%
6
American Journal of Gastroenterology
15 papers in training set
Top 0.1%
3.6%
7
Drug and Alcohol Dependence
37 papers in training set
Top 0.3%
3.6%
8
Addiction Biology
47 papers in training set
Top 0.4%
2.9%
9
Psychological Medicine
74 papers in training set
Top 0.8%
2.1%
50% of probability mass above
10
Neuropsychopharmacology
134 papers in training set
Top 1%
1.8%
11
Addiction
25 papers in training set
Top 0.2%
1.8%
12
Biomedicines
66 papers in training set
Top 0.9%
1.7%
13
American Journal of Psychiatry
20 papers in training set
Top 0.1%
1.7%
14
Psychopharmacology
59 papers in training set
Top 0.4%
1.7%
15
Alcoholism: Clinical and Experimental Research
13 papers in training set
Top 0.2%
1.7%
16
Nicotine and Tobacco Research
13 papers in training set
Top 0.1%
1.5%
17
Journal of Clinical Medicine
91 papers in training set
Top 4%
1.3%
18
PeerJ
261 papers in training set
Top 10%
1.2%
19
JAMA Psychiatry
13 papers in training set
Top 0.3%
1.2%
20
JAMA Network Open
127 papers in training set
Top 3%
1.2%
21
Cureus
67 papers in training set
Top 3%
1.2%
22
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.2%
23
BMJ Open
554 papers in training set
Top 11%
1.2%
24
Psychiatry Research
35 papers in training set
Top 1%
1.0%
25
The British Journal of Psychiatry
21 papers in training set
Top 0.8%
1.0%
26
International Journal of Drug Policy
11 papers in training set
Top 0.3%
0.8%
27
Cancers
200 papers in training set
Top 4%
0.8%
28
Journal of Psychiatric Research
28 papers in training set
Top 0.7%
0.8%
29
Molecular Psychiatry
242 papers in training set
Top 3%
0.8%
30
Journal of Affective Disorders
81 papers in training set
Top 2%
0.8%